Company intelligence / Profile preview

Gerostate Alpha

Novato, California, United Statesgerostatealpha.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has identified lead compounds that show promise in extending lifespan in C. elegans nematodes and is working to establish which compounds are most effective at promoting health and slowing aging[4][5]

Therapeutic areas: Other
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

MIC

Pre-clinical

Indications: Aging, Age-related diseases, Neurodegenerative diseases

Partnerships

Buck Institute for Research on Aging (incubation partner)

Beyond the preview

Go deeper on Gerostate Alpha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gerostate Alpha.

Explore the full profile